Home/Biosimilar Atlas/Companies/Dong-A ST

Dong-A ST

Biosimilar developer, South Korea. 1 development product across 1 molecule: ustekinumab.

First approval in the Atlas: Oct 2024, Imuldosa, ustekinumab (FDA)
FDAproducts approved1
EMAproducts approved1
MHRAproducts approved1
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered1
Connections
1molecule1product4 of 7markets0candidates in trials6companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
UstekinumabImuldosa DMB-3115Oct 2024Dec 2024MHRA···May 20254/7

Month shown is the first approval or registration of that product in that market.

Companies on the same molecules

Developers whose portfolios overlap most with Dong-A ST, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

AlvotechOne shared molecule: ustekinumab5 molecules in its portfolioAmgenOne shared molecule: ustekinumab8 molecules in its portfolioBio-Thera SolutionsOne shared molecule: ustekinumab3 molecules in its portfolioBiocon BiologicsOne shared molecule: ustekinumab9 molecules in its portfolioCelltrionOne shared molecule: ustekinumab10 molecules in its portfolioFormyconOne shared molecule: ustekinumab2 molecules in its portfolio

Chronology

Compare Dong-A ST with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.